$17.46
1.93% yesterday
Nasdaq, Dec 04, 10:04 pm CET

Adaptive Biotechnologies Corp Stock price

$17.46
+0.54 3.19% 1M
+7.48 74.95% 6M
+11.47 191.24% YTD
+11.32 184.36% 1Y
+9.21 111.64% 3Y
-30.32 63.46% 5Y
-2.54 12.70% 10Y
-2.54 12.70% 20Y
Nasdaq, Closing price Thu, Dec 04 2025
+0.33 1.93%

Key metrics

Basic
Market capitalization
$2.6b
Enterprise Value
$2.5b
Net debt
positive
Cash
$212.8m
Shares outstanding
152.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
10.3 | 10.7
EV/Sales
10.0 | 10.4
EV/FCF
negative
P/B
12.8
Financial Health
Equity Ratio
37.6%
Return on Equity
-78.7%
ROCE
-19.2%
ROIC
-
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$252.8m | $244.2m
EBITDA
$-66.7m | $-49.4m
EBIT
$-78.4m | $-109.5m
Net Income
$-79.9m | $-105.6m
Free Cash Flow
$-62.4m
Growth (TTM | estimate)
Revenue
42.6% | 36.4%
EBITDA
57.2% | 66.0%
EBIT
53.1% | 29.5%
Net Income
59.0% | 33.8%
Free Cash Flow
45.6%
Margin (TTM | estimate)
Gross
71.8%
EBITDA
-26.4% | -20.2%
EBIT
-31.0%
Net
-31.6% | -43.3%
Free Cash Flow
-24.7%
More
EPS
$-0.5
FCF per Share
$-0.4
Short interest
8.7%
Employees
619
Rev per Employee
$290.0k
Show more

Is Adaptive Biotechnologies Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Adaptive Biotechnologies Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Adaptive Biotechnologies Corp forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Adaptive Biotechnologies Corp forecast:

Buy
86%
Hold
14%

Financial data from Adaptive Biotechnologies Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
253 253
43% 43%
100%
- Direct Costs 71 71
3% 3%
28%
182 182
75% 75%
72%
- Selling and Administrative Expenses 163 163
2% 2%
65%
- Research and Development Expense 85 85
14% 14%
34%
-67 -67
57% 57%
-26%
- Depreciation and Amortization 12 12
2% 2%
5%
EBIT (Operating Income) EBIT -78 -78
53% 53%
-31%
Net Profit -80 -80
59% 59%
-32%

In millions USD.

Don't miss a Thing! We will send you all news about Adaptive Biotechnologies Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adaptive Biotechnologies Corp Stock News

Neutral
GlobeNewsWire
10 days ago
SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included i...
Neutral
GlobeNewsWire
28 days ago
SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UKPresenta...
Neutral
Seeking Alpha
28 days ago
Adaptive Biotechnologies Corporation ( ADPT ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Karina Calzadilla - Vice President of Investor Relations Chad Robins - Co-Founder, CEO & Chairman Kyle Piskel - VP, CFO & Principal Accounting Officer Susan Bobulsky - Chief Commercial Officer of MRD Conference Call Participants Mark Massaro - BTIG, LLC, Research Division Subbu ...
More Adaptive Biotechnologies Corp News

Company Profile

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Head office United States
CEO Chad Robins
Employees 619
Founded 2009
Website www.adaptivebiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today